A prospective study comparing the predictions of doctors versus models for treatment outcome of lung cancer patients: A step toward individualized care and shared decision making

Radiotherapy and Oncology

Volumn 112, Issue 1, 2014, Pages 37-43

  Oberije, Cary ^a   Nalbantov, Georgi ^a   Dekker, Andre ^a   Boersma, Liesbeth ^a   Borger, Jacques ^a   Reymen, Bart ^a   Van Baardwijk, Angela ^a   Wanders, Rinus ^a   De Ruysscher, Dirk ^b   Steyerberg, Ewout ^c   Dingemans, Anne Marie ^a   Lambin, Philippe ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Lung cancer; Prediction models

Indexed keywords

ADULT; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CHEMORADIOTHERAPY; CLINICAL ASSESSMENT; CLINICAL DECISION MAKING; CLINICAL PRACTICE; COMPARATIVE STUDY; CONSULTATION; CONTROLLED STUDY; DYSPHAGIA; DYSPNEA; FEMALE; HIGH RISK POPULATION; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHYSICIAN ATTITUDE; PREDICTION; PROSPECTIVE STUDY; RADIATION ONCOLOGIST; SMALL CELL LUNG CANCER; STATISTICAL MODEL; TREATMENT OUTCOME; ADVERSE EFFECTS; AGED; CLINICAL COMPETENCE; DECISION MAKING; DECISION SUPPORT SYSTEM; DEGLUTITION DISORDERS; LUNG NEOPLASMS; MIDDLE AGED; PERSONALIZED MEDICINE; PROBABILITY; RADIATION INJURIES;

AGED; AREA UNDER CURVE; CHEMORADIOTHERAPY; CLINICAL COMPETENCE; DECISION MAKING; DECISION SUPPORT TECHNIQUES; DEGLUTITION DISORDERS; DYSPNEA; FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MODELS, STATISTICAL; PROBABILITY; PROSPECTIVE STUDIES; RADIATION INJURIES; TREATMENT OUTCOME;

EID: 84908222160     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2014.04.012     Document Type: Article

References (41)

1. Lambin P, van Stiphout RGPM, Starmans MHW, Rios-Velazquez E, Nalbantov G, Aerts HJWL, et al. Predicting outcomes in radiation oncology-multifactorial decision support systems. Nat Rev Clin Oncol 2012;10:27-40.
2. Steyerberg EW, Moons KGM, van der Windt DA, Hayden JA, Perel P, Schroter S, et al. Prognosis research strategy (PROGRESS) 3: prognostic model research. PLoS Med 2013;10:e1001381.
3. Dehing-Oberije C, Yu S, De Ruysscher D, Meersschout S, Van Beek K, Lievens Y, et al. Development and external validation of prognostic model for 2-year survival of non-small-cell lung cancer patients treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys 2009;74:355-62.
4. Dehing-Oberije C, De Ruysscher D, Petit S, Van Meerbeeck J, Vandecasteele K, De Neve W, et al. Development, external validation and clinical usefulness of a practical prediction model for radiation-induced dysphagia in lung cancer patients. Radiother Oncol 2010;97:455-61.
5. Dehing-Oberije C, De Ruysscher D, van Baardwijk A, Yu S, Rao B, Lambin P. The importance of patient characteristics for the prediction of radiation-induced lung toxicity. Radiother Oncol 2009;91:421-6.
6. Grove WM, Meehl PE. Comparative efficiency of informal (subjective, impressionistic) and formal (mechanical, algorithmic) prediction procedures: the clinical-statistical controversy. Psychol Public Policy Law 1996;2:293.
7. Clément-Duchêne C, Carnin C, Guillemin F, Martinet Y. How accurate are physicians in the prediction of patient survival in advanced lung cancer? Oncologist 2010;15:782-9.
8. Glare P, Virik K, Jones M, Hudson M, Eychmuller S, Simes J, et al. A systematic review of physicians' survival predictions in terminally ill cancer patients. BMJ 2003;327:195.
9. Mackillop WJ, Quirt CF. Measuring the accuracy of prognostic judgments in oncology. J Clin Epidemiol 1997;50:21-9.
10. Chow E, Davis L, Panzarella T, Hayter C, Szumacher E, Loblaw A, et al. Accuracy of survival prediction by palliative radiation oncologists. Radiat Oncol Biol 2005;61:870-3.
11. Jeldres C. Life expectancy estimation in prostate cancer patients. Can Urol Assoc J 2012;6:374-5.
12. Ross PL, Gerigk C, Gonen M, Yossepowitch O, Cagiannos I, Sogani PC, et al. Comparisons of nomograms and urologists' predictions in prostate cancer. Semin Urol Oncol 2002;20:82-8.
13. Ball D, Smith J, Wirth A, Mac Manus M. Failure of T stage to predict survival in patients with non-small-cell lung cancer treated by radiotherapy with or without concomitant chemotherapy. Radiat Oncol Biol 2002;54:1007-13.
14. Oberije C, Liao Z, De Ruysscher D, Tucker S, Lambin P. Development and external validation of a model for prediction of radiation-induced dyspnea: an approach combining clinical data with information from literature. Int J Radiat Oncol Biol Phys 2010;78:S528EP.
15. De Ruysscher D, Bremer R-H, Koppe F, Wanders S, van Haren E, Hochstenbag M, et al. Omission of elective node irradiation on basis of CT-scans in patients with limited disease small cell lung cancer: a phase II trial. Radiother Oncol 2006;80:307-12.
16. Senan S, De Ruysscher D, Giraud P, Mirimanoff R, Budach V. Radiotherapy Group of European Organization for Research and Treatment of Cancer. Literature-based recommendations for treatment planning and execution in high-dose radiotherapy for lung cancer. Radiother Oncol 2004;71:139-46.
17. van Baardwijk A, Wanders S, Boersma L, Borger J, Öllers M, Dingemans A-MC, et al. Mature results of an individualized radiation dose prescription study based on normal tissue constraints in stages I to III non-small-cell lung cancer. J Clin Oncol 2010;28:1380-6.
18. van Baardwijk AA, Reymen BB, Wanders SS, Borger JJ, Ollers MM, Dingemans AMCA, et al. Mature results of a phase II trial on individualised accelerated radiotherapy based on normal tissue constraints in concurrent chemo-radiation for stage III non-small cell lung cancer. Eur J Cancer 2012;48:2339-46.
19. Turrisi AT, Kim K, Blum R, Sause WT, Livingston RB, Komaki R, et al. Twicedaily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999;340:265-71.
20. De Ruysscher D, Faivre-Finn C, Nestle U, Hurkmans CW, Le Péchoux C, Price A, et al. European organisation for research and treatment of cancer recommendations for planning and delivery of high-dose, high-precision radiotherapy for lung cancer. J Clin Oncol 2010;28:5301-10.
21. Marks LB, Bentzen SM, Deasy JO, Kong F-MS, Bradley JD, Vogelius IS, et al. Radiation dose-volume effects in the lung. Int J Radiat Oncol Biol Phys 2010;76:S70-6.
22. Cox DR. Note on grouping. J Am Stat Assoc 1957;52:543-7.
23. Viganò A, Dorgan M, Bruera E, Suarez Almazor ME. The relative accuracy of the clinical estimation of the duration of life for patients with end of life cancer. Cancer 2000;86:170-6.
24. Stone P, Lund S. Predicting prognosis in patients with advanced cancer. Ann Oncol 2007;18:971-6.
25. Stockler MR, Tattersall MHN, Boyer MJ, Clarke SJ, Beale PJ, Simes RJ. Disarming the guarded prognosis: predicting survival in newly referred patients with incurable cancer. Br J Cancer 2006;94:208-12.
26. Christakis NA, Lamont EB. Extent and determinants of error in doctors' prognoses in terminally ill patients: prospective cohort study. BMJ 2000;320:469-72.
27. Dehing-Oberije C, De Ruysscher D, van der Weide H, Hochstenbag M, Bootsma G, Geraedts W, et al. Tumor volume combined with number of positive lymph node stations is a more important prognostic factor than TNM stage for survival of non-small-cell lung cancer patients treated with (chemo)radiotherapy. Radiat Oncol Biol 2008;70:1039-44.
28. Ball D, Mitchell A, Giroux D, Rami-Porta R. IASLC Staging Committee and Participating Institutions. Effect of tumor size on prognosis in patients treated with radical radiotherapy or chemoradiotherapy for non-small cell lung cancer. An analysis of the staging project database of the International Association for the Study of Lung Cancer. J Thorac Oncol 2013;8:315-21.
29. Soliman M, Yaromina A, Appold S, Zips D, Reiffenstuhl C, Schreiber A, et al. GTV differentially impacts locoregional control of non-small cell lung cancer (NSCLC) after different fractionation schedules: subgroup analysis of the prospective randomized CHARTWEL trial. Radiother Oncol 2013;106:299-304.
30. Werner-Wasik M, Swann RS, Bradley J, Graham M, Emami B, Purdy J, et al. Increasing tumor volume is predictive of poor overall and progression-free survival: secondary analysis of the Radiation Therapy Oncology Group 93-11 phase I-II radiation dose-escalation study in patients with inoperable non-small- cell lung cancer. Radiat Oncol Biol 2008;70:385-90.
31. Nalbantov G, Kietselaer B, Vandecasteele K, Oberije C, Berbee M, Troost E, et al. Cardiac comorbidity is an independent risk factor for radiation-induced lung toxicity in lung cancer patients. Radiother Oncol 2013;109:100-6.
32. Tang C, Liao Z, Zhuang Y, Levy LB, Hung C, Li X, et al. Acute phase response before treatment predicts radiation esophagitis in non-small cell lung cancer. Radiother Oncol 2014;110:493-8.
33. Bornstein BH, Emler AC. Rationality in medical decision making: a review of the literature on doctors' decision-making biases. J Eval Clin Pract 2001;7:97-107.
34. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 1994;151:1283-90.
35. Schröder FH, van der Cruijsen-Koeter I, de Koning HJ, Vis AN, Hoedemaeker RF, Kranse R. Prostate cancer detection at low prostate specific antigen. J Urol 2000;163:806-12.
36. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level 64.0 ng per milliliter. N Engl J Med 2004;350:2239-46.
37. Langendijk JA, Lambin P, De Ruysscher D, Widder J, Bos M, Verheij M. Selection of patients for radiotherapy with protons aiming at reduction of side effects: the model-based approach. Radiother Oncol 2013;107:267-73.
38. Trott K-R, Doerr W, Facoetti A, Hopewell J, Langendijk J, van Luijk P, et al. Biological mechanisms of normal tissue damage: importance for the design of NTCP models. Radiother Oncol 2012;105:79-85.
39. Lambin P, Rios-Velazquez E, Leijenaar R, Carvalho S, van Stiphout RGPM, Granton P, et al. Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer 2012;48:441-6.
40. Bentzen SM. From cellular to high-throughput predictive assays in radiation oncology: challenges and opportunities. Semin Radiat Oncol 2008;18:75-88.
41. Starmans MHW, Lieuwes NG, Span PN, Haider S, Dubois L, Nguyen F, et al. Independent and functional validation of a multi-tumour-type proliferation signature. Br J Cancer 2012;107:508-15.